NetworkNewsBreaks – Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) Reports Encouraging Results from Phase 2 Proof-of-Concept Study of Developmental RTU Glucagon
Xeris Pharmaceuticals (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today reported encouraging findings from the outpatient stage of a Phase 2 proof-of-concept study of its developmental ready-to-use (“RTU”) glucagon in patients who experience postprandial hypoglycemic episodes following bariatric surgery. Among other highlights, results from the 12 subject, 12-week outpatient stage demonstrated that, during episodes when blood sugar was <70 mg/dL at drug dosing and without the use of glucose tabs, RTU glucagon successfully restored blood glucose levels to normal levels (blood sugar ≥70 mg/dL) within…
